{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:37:49Z","timestamp":1793090269005,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023LZY002"],"award-info":[{"award-number":["ZR2023LZY002"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn 202312374"],"award-info":[{"award-number":["tsqn 202312374"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105628","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:22:08Z","timestamp":1790688128000},"page":"105628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Menin inhibitors in acute myeloid leukaemia: Mechanisms, clinical pharmacology, and emerging therapeutic strategies"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7631-4880","authenticated-orcid":false,"given":"Chenchen","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.critrevonc.2026.105628_bib1","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib2","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1182\/blood-2025-5207","article-title":"A multicenter phase 1 trial evaluating the safety and preliminary efficacy of revumenib as post-transplant maintenance after allogeneic hematopoietic cell transplant in patients with KMT2A-rearranged or NPM1-mutated acute leukemia","volume":"146","author":"Ball","year":"2025","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib3","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1182\/blood-2025-3427","article-title":"Preliminary results of A phase 1 study of the safety and tolerability of the combination of revumenib (REV) with gilteritinib (GILT) in Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML)","volume":"146","author":"Borate","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105628_bib4","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.trecan.2025.06.002","article-title":"Advances in menin inhibition in acute myeloid leukemia","volume":"11","author":"Boussi","year":"2025","journal-title":"Trends Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105628_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13070227","article-title":"Therapeutic implications of menin inhibitors in the treatment of acute leukemia: a critical review","volume":"13","author":"Canichella","year":"2025","journal-title":"Diseases"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105628_bib6","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.3324\/haematol.2022.281927","article-title":"Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1\/FLT3-ITD\/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model","volume":"108","author":"Carter","year":"2023","journal-title":"Haematologica"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib7","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2025-3461","article-title":"Post-transplant maintenance with revumenib in children with HOX-driven AML","volume":"146","author":"Cuglievan","year":"2025","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2025-763","article-title":"Monotherapy update from Phase 1 portion in Phase1\/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105628_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16223743","article-title":"Targeting menin in acute myeloid leukemia: therapeutic advances and future directions","volume":"16","author":"Dhiman","year":"2024","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105628_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib11","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1182\/blood-2025-5199","article-title":"Bleximenib in combination with intensive chemotherapy: a phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations","volume":"146","author":"D\u00f6hner","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105628_bib12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105628_bib13","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib14","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2025-1497","article-title":"Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models","volume":"146","author":"Fiskus","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105628_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","article-title":"Targeting of epigenetic co-dependencies enhances anti-AML efficacy of menin inhibitor in AML with MLL1-r or mutant NPM1","volume":"13","author":"Fiskus","year":"2023","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105628_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114901","article-title":"NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML","volume":"43","author":"Heikamp","year":"2024","journal-title":"Cell. Rep."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105628_bib17","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"Update measurable residual disease in acute myeloid leukemia: European leukemianet working party consensus document","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2025-764","article-title":"Ziftomenib in combination with venetoclax and azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a\/b safety and clinical activity results from KOMET-007","volume":"146","author":"Issa","year":"2025","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib19","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2025-3428","article-title":"Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML","volume":"146","author":"Issa","year":"2025","journal-title":"Blood"},{"issue":"7954","key":"10.1016\/j.critrevonc.2026.105628_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib21","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1182\/blood-2025-3429","volume":"146","author":"Jabbour","year":"2025","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib22","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1182\/blood-2025-5211","article-title":"Trial in progress: A phase II study of ziftomenib monotherapy in unfit patients with newly diagnosed acute myeloid leukemia with NPM1 mutation or KMT2A rearrangement","volume":"146","author":"Jain","year":"2025","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2025-47","article-title":"Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML","volume":"146","author":"Jen","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105628_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2023.104869","article-title":"Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX\/MEIS1 expression","volume":"66","author":"Juul-Dam","year":"2023","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.critrevonc.2026.105628_bib25","unstructured":"Komzifti (ziftomenib) capsules, for oral use: US prescribing information. San Diego (CA): Kura Oncology, Inc.; issued November 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=b650f696-3391-4274-8b55-a5f5e9d04769. Accessed 14 September 2026."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105628_bib26","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/bjh.19508","article-title":"The Menin story in acute myeloid leukaemia-the road to success","volume":"205","author":"Kuhn","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105628_bib27","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"issue":"41","key":"10.1016\/j.critrevonc.2026.105628_bib28","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105628_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-026-02291-4","article-title":"Ziftomenib: first approval","volume":"86","author":"McGuigan","year":"2026","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105628_bib30","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41375-023-01882-4","article-title":"Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1","volume":"37","author":"Mill","year":"2023","journal-title":"Leukemia"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib31","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1182\/blood-2025-5206","article-title":"Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia: preliminary results from the phase 1b etctn 10596 study","volume":"146","author":"Mims","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105628_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41556-025-01859-8","article-title":"DOT1L provides transcriptional memory through PRC1.1 antagonism","volume":"28","author":"Neville","year":"2026","journal-title":"Nat. Cell. Biol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib33","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1182\/blood-2025-5200","article-title":"Phase 1b study of bleximenib in combination with venetoclax in acute myeloid leukemia with KMT2A or NPM1 alterations","volume":"146","author":"O'Nions","year":"2025","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib34","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1182\/blood-2025-5248","article-title":"Additional genetic targets are present in the majority of AML patients with NPM1, KMT2A or NUP98 aberrations potentially impacting combination therapy with menin inhibitors","volume":"146","author":"Ordemann","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105628_bib35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ijc.35332","article-title":"Targeting the menin-KMT2A interaction in leukemia: lessons learned and future directions","volume":"158","author":"Perner","year":"2026","journal-title":"Int. J. Cancer"},{"issue":"7954","key":"10.1016\/j.critrevonc.2026.105628_bib36","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib37","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2025-1654","volume":"146","author":"Raaijmakers","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105628_bib38","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3324\/haematol.2022.282160","article-title":"Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax","volume":"108","author":"Rausch","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105628_bib39","unstructured":"Revuforj (revumenib) tablets, for oral use: US prescribing information. New York (NY): Syndax Pharmaceuticals, Inc.; revised February 2026. https:\/\/dailymed.nlm.nih.gov\/dailymed\/. Accessed 14 September 2026."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105628_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40487-024-00262-x","article-title":"Small molecule menin inhibitors: novel therapeutic agents targeting acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation","volume":"12","author":"Thomas","year":"2024","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105628_bib41","unstructured":"Venclexta (venetoclax) tablets, for oral use: US prescribing information. North Chicago (IL): AbbVie Inc.; revised March 2026. https:\/\/dailymed.nlm.nih.gov\/dailymed\/. Accessed 14 September 2026."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105628_bib42","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"issue":"31","key":"10.1016\/j.critrevonc.2026.105628_bib43","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in relapsed or refractory NPM1-mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105628_bib44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","article-title":"Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia","volume":"13","author":"Wang","year":"2023","journal-title":"Cancer Discov."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1182\/blood-2025-765","article-title":"Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory acute myeloid leukemia","volume":"146","author":"Watts","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105628_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","article-title":"Novel therapeutic targets in acute myeloid leukemia (AML)","volume":"26","author":"Wysota","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105628_bib47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ccr.2008.05.003","article-title":"Menin critically links MLL proteins with LEDGF on cancer-associated target genes","volume":"14","author":"Yokoyama","year":"2008","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105628_bib48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","article-title":"Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies","volume":"13","author":"Zehtabcheh","year":"2025","journal-title":"Biomark. Res."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105628_bib49","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105628_bib50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 results: first-in-human phase 1\/2 study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105628_bib51","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:04:40Z","timestamp":1793088280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":51,"alternative-id":["S1040842826005159"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105628","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Menin inhibitors in acute myeloid leukaemia: Mechanisms, clinical pharmacology, and emerging therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105628"}}